NASDAQ:LAB Standard BioTools (LAB) Stock Price, News & Analysis $1.27 +0.07 (+5.83%) Closing price 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Standard BioTools Stock (NASDAQ:LAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Standard BioTools alerts:Sign Up Key Stats Today's Range$1.19▼$1.2950-Day Range$1.02▼$1.4752-Week Range$0.92▼$2.32Volume2.07 million shsAverage Volume1.75 million shsMarket Capitalization$485.13 millionP/E RatioN/ADividend YieldN/APrice Target$1.55Consensus RatingHold Company Overview Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Read More Standard BioTools Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreLAB MarketRank™: Standard BioTools scored higher than 51% of companies evaluated by MarketBeat, and ranked 352nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingStandard BioTools has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageStandard BioTools has only been the subject of 2 research reports in the past 90 days.Read more about Standard BioTools' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Standard BioTools are expected to grow in the coming year, from ($0.29) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Standard BioTools is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Standard BioTools is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStandard BioTools has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Standard BioTools' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.31% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Standard BioTools has recently decreased by 2.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStandard BioTools does not currently pay a dividend.Dividend GrowthStandard BioTools does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.31% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Standard BioTools has recently decreased by 2.67%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.19 News SentimentStandard BioTools has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Standard BioTools this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for LAB on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows4 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Standard BioTools insiders have bought 1,066.85% more of their company's stock than they have sold. Specifically, they have bought $442,446.00 in company stock and sold $37,918.00 in company stock.Percentage Held by Insiders23.16% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Standard BioTools' insider trading history. Receive LAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Email Address LAB Stock News HeadlinesStandard BioTools Inc. (NASDAQ:LAB) Director Purchases $98,250.00 in StockAugust 16, 2025 | insidertrades.comStandard BioTools (NASDAQ:LAB) Raised to "Hold" at Wall Street ZenAugust 18, 2025 | americanbankingnews.comTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your spot for FREE.August 22 at 2:00 AM | Crypto 101 Media (Ad)Standard BioTools (NASDAQ:LAB) Downgraded by TD Cowen to HoldAugust 15, 2025 | americanbankingnews.comStandard BioTools downgraded to Hold from Buy at TD CowenAugust 13, 2025 | msn.comStandard BioTools Delays Quarterly Report FilingAugust 12, 2025 | tipranks.comStandard BioTools Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comWhat to Expect from Standard BioTools Inc (LAB) Q2 2025 EarningsAugust 10, 2025 | finance.yahoo.comSee More Headlines LAB Stock Analysis - Frequently Asked Questions How have LAB shares performed this year? Standard BioTools' stock was trading at $1.75 at the start of the year. Since then, LAB stock has decreased by 28.9% and is now trading at $1.2450. Who are Standard BioTools' major shareholders? Standard BioTools' top institutional investors include Geode Capital Management LLC (1.96%), Sumitomo Mitsui Trust Group Inc. (1.62%), Nikko Asset Management Americas Inc. (1.62%) and Mirabella Financial Services LLP (0.90%). Insiders that own company stock include Casdin Partners Master Fund, L, Michael Egholm, Hanjoon Alex Kim and Sean Mackay. View institutional ownership trends. How do I buy shares of Standard BioTools? Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Standard BioTools own? Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Today8/22/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:LAB CIK1162194 Webwww.fluidigm.com Phone(650) 266-6000Fax650-871-7152Employees620Year FoundedN/APrice Target and Rating Average Price Target for Standard BioTools$1.55 High Price Target$1.55 Low Price Target$1.55 Potential Upside/Downside+29.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.88 million Net Margins-69.08% Pretax Margin-71.85% Return on Equity-20.23% Return on Assets-15.32% Debt Debt-to-Equity RatioN/A Current Ratio5.16 Quick Ratio5.37 Sales & Book Value Annual Sales$174.43 million Price / Sales2.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.11 per share Price / Book1.08Miscellaneous Outstanding Shares381,990,000Free Float293,525,000Market Cap$458.39 million OptionableOptionable Beta1.32 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LAB) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.